Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 16/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.77 |
| ▸ | MEN1 | O00255 | 1/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL644749 | 0.87 | ALPL (1.00) | ALPLMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL31371215 | 0.87 | ALPL (1.00) | ALPLALDH1A1LMNA | |
| SCHEMBL15211944 | 0.87 | ALPL (1.00) | ALPLALDH1A1LMNA | |
| SCHEMBL15212055 | 0.80 | ALPL (1.00) | ALPLALDH1A1LMNA | |
| SCHEMBL13539330 | 0.79 | ALPL (0.80) | ALPLKMT2ALMNA | |
| SCHEMBL15211862 | 0.76 | ALPL (1.00) | ALPL | |
| SCHEMBL1404363 | 0.75 | ALPL (0.60) | ALPLMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL7536242 | 0.74 | LMNA (0.73) | ALPLMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL13539338 | 0.73 | ALPL (1.00) | ALPLALDH1A1 | |
| SCHEMBL644500 | 0.73 | ALPL (1.00) | ALPLMAPK1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2291372-A2 | INTESTINAL ALKALINE PHOSPHATASE MODULATORS AND USES THEREOF | Burnham Institute for Medical Research (US) | 2011-03-09 | — | — | EP | disclosed |
| US-20100016313-A1 | INTESTINAL ALKALINE PHOSPHATASE MODULATORS AND USES THEREOF | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100016313-A1 | INTESTINAL ALKALINE PHOSPHATASE MODULATORS AND USES THEREOF | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-01-21 | — | — | US | disclosed |
| WO-2009143150-A2 | INTESTINAL ALKALINE PHOSPHATASE MODULATORS AND USES THEREOF | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016313-A1 | INTESTINAL ALKALINE PHOSPHATASE MODULATORS AND USES THEREOF | ALPI, SI, FABP2 | ALPL 5/4885MAPK1 4003/4885MEN1 4150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.